Brief: Medincell Provides Update On Phase 3 Mdc-Cwm Clinical Trial

Medincell SA

14/05/2024 17:02

May 14 (Reuters) - Medincell SA  MEDCL.PA :
    * MEDINCELL PROVIDES UPDATE ON PHASE 3 MDC-CWM CLINICAL
TRIAL
    * MEDINCELL SA -  PHASE 3 TRIAL FOR F14 DID NOT MEET ITS
PRIMARY
ENDPOINT OF TIME-WEIGHTED AUC OF PAIN INTENSITY OVER 14 DAYS
    * MEDINCELL SA: SAFETY PROFILE FOR F14 WAS CONSISTENT WITH
PRIOR
PHASE 2 STUDY, AND NO NEW SAFETY SIGNALS WERE IDENTIFIED, AND NO
SAES WERE REPORTED
    * MEDINCELL- AIC INTENDS TO DISCUSS RESULTS FROM THIS TRIAL
WITH
REGULATORS,EXPLORE ALTERNATIVE APPROVAL PATHWAYS FOR F14 IN THIS
SUB-GROUP OF PATIENTS

Source text for Eikon:  ID:nBw31BLXha 
Further company coverage:  MEDCL.PA 

 ((Reuters.Briefs@thomsonreuters.com;))